Natural history of chronic hepatitis B: what exactly has REVEAL revealed?
about
Hepatitis B or C viral infection and risk of pancreatic cancer: a meta-analysis of observational studiesReview of Laboratory Tests used in Monitoring Hepatitis B Response to Pegylated Interferon and Nucleos(t)ide Analog TherapyA current update on the rule of alternative and complementary medicine in the treatment of liver diseasesImmune therapy for hepatitis BMultiplicative synergistic risk of hepatocellular carcinoma development among hepatitis B and C co-infected subjects in HBV endemic area: a community-based cohort study.Prognostic values of fluctuations in serum levels of alanine transaminase in inactive carrier state of HBV infection.Mushroom lectin overcomes hepatitis B virus tolerance via TLR6 signaling.Characteristics and management of patients with chronic hepatitis B in an integrated care settingAndrogen receptor roles in hepatocellular carcinoma, fatty liver, cirrhosis and hepatitis.Differential plasma microRNA profiles in HBeAg positive and HBeAg negative children with chronic hepatitis BDesigning immune therapy for chronic hepatitis B.Hepatitis B virus genotype distribution and genotype-specific BCP/preCore substitutions in acute and chronic infections in Argentina.Changes in serum alanine aminotransferase levels in telbivudine versus lamivudine treatment for chronic hepatitis B: a meta-analysis.Children with Chronic Hepatitis B in the United States and Canada.Efficacy Comparison of Tenofovir and Entecavir in HBeAg-Positive Chronic Hepatitis B Patients with High HBV DNAThe Efficacy of Add-on Telbivudine Versus Switching to Pegylated Interferon Alfa-2a in Chronic Hepatitis B Patients With Poor Responses to AdefovirHepatitis-Associated Liver Cancer: Gaps and Opportunities to Improve Care.Lower liver cancer risk with antiviral therapy in chronic hepatitis B patients with normal to minimally elevated ALT and no cirrhosis.The status of HBV infection influences metastatic pattern and survival in Chinese patients with pancreatic cancer.Female gender lost protective effect against disease progression in elderly patients with chronic hepatitis B.Why do I treat HBeAg-positive chronic hepatitis B patients with a nucleoside analogue.Entecavir for the treatment of patients with hepatitis B virus-related decompensated cirrhosis.Non-antigen-specific and antigen-specific immune therapies for chronic hepatitis B: evidences from laboratory benches and patient's bedsides.HBeAg-positive chronic hepatitis B: why do i treat my patients with Nucleos(t)ide analogs?Core promoter: a critical region where the hepatitis B virus makes decisions.Re-appraisal of old and new diagnostic tools in the current management of chronic hepatitis B.Novel insights into immunotherapy for hepatitis B patients.Clinical relevance of the study of hepatitis B virus covalently closed circular DNA.Prognosis and predictors of hepatocellular carcinoma in elderly patients infected with hepatitis B virus.Tolerability, pharmacokinetics and antiviral activity of rHSA/IFNα2a for the treatment of chronic hepatitis B infection.Vitamin E for the treatment of E-antigen-positive chronic hepatitis B in paediatric patients: results of a randomized phase 2 controlled study.Familial clustering of hepatocellular carcinoma in HBsAg-positive patients in the United States.Favorable outcome of extended treatment with adding pegylated Interferonα-2a to entecavir for HBeAg-positive chronic hepatitis B: a case report.IL6 gene allele-specific C/EBPα-binding activity affects the development of HBV infection through modulation of Th17/Treg balance.High treatment modification rates with lamivudine therapy in HBV-infected patients with low baseline viremia and early virological response: A multicenter study.SNP rs7770370 in HLA-DPB1 loci as a major genetic determinant of response to booster hepatitis B vaccination: results of a genome-wide association study.Effect of hepatic steatosis on the progression of chronic hepatitis B: A prospective cohort and in vitro study.Association between extranodal natural killer/T-cell lymphoma and hepatitis B viral infection: a case-control study.Viral suppression and cirrhosis regression with tenofovir disoproxil fumarate in Asians with chronic hepatitis B.Spontaneous seroclearance of hepatitis B seromarkers and subsequent risk of hepatocellular carcinoma.
P2860
Q22305489-EF4AF825-25A1-41C9-8AB9-3E06D4B34D09Q26740161-1A455F2E-B2DB-47DC-8DD3-FD8D15EA1C91Q27012998-00EB04D9-57D3-458B-A70E-A4A237F56AB2Q28078856-417DFF55-3EB0-4AB4-B54C-E141D4E0D7E8Q31102359-6DAD6DC5-728C-4EF9-BD8F-613AF95A90D1Q33580037-0059B97F-9E7D-4976-A022-A5A7F3394410Q33918915-785570C8-ACD7-44AA-9428-E32D34217A35Q34110725-45E8B27D-95E2-4C1C-8975-5D984CFC69EDQ34194760-706153FA-555E-455D-849D-AEA87878C40EQ34613446-7D29577B-27E7-451D-BBF8-F5505E24BF53Q34825732-594B1817-F1C7-4BED-9CF8-10995A724942Q35231194-76CCDD7A-D13A-47A1-A45E-2258D4B39B96Q35562322-0D946148-2F95-4A04-BAF4-BAB1CE95DAD5Q36327587-253E4820-1FFA-402E-9E9B-FD923946DB7BQ36686179-DFDD402D-7EB5-41B4-8974-0605E03797EBQ36805368-4DB9A003-0AFA-4FC0-9BA5-27C0F3E8B529Q36871021-7D1C4A05-8853-427F-988A-48AD369AB2C1Q37165101-52497D59-4AA2-40C5-A1A9-552F492CF43BQ37365328-706FCC64-C251-4FFE-B069-331A36DAA483Q37444202-2A0BA1AC-873A-4829-BD00-3D9470760B04Q38071399-2EC8EA5F-7ACC-4C88-8BB4-C9FAE29D62A6Q38096069-21A1D871-5F27-4E46-895E-60A52149852AQ38098583-7F9736BF-B22D-492C-8C67-4D98E1C079FBQ38174258-ECA7F2C0-4E09-4FA8-82F4-DFC6BBA8407DQ38191563-2DDF38AC-5488-4DC8-9B05-52E967BE77E6Q38237418-594A461F-5145-4725-AF4F-5FE0541B8101Q38655228-B3474B02-A2C0-417B-BC44-94D3B74184B6Q38685587-AE0AD6E2-5CC9-46EE-BB9D-E64AF39C038AQ40138677-2F99D435-7D3C-4C41-BEAC-0646B6D3172BQ40445667-59758128-5341-41AA-892C-A6B72FEBFA4DQ40687503-699D993A-3C7F-49BD-A2BE-74504A4EC509Q40706745-AF78BB59-C21A-4663-A4F7-001B02CEB25BQ40832139-A1046A9E-AB34-4949-A6EC-704A8F78C1ECQ40961789-CE4AB33C-CA7C-4B32-8AC8-4A13DBC1ABB8Q41467947-D434DE13-5055-430D-A57A-88D3760AB06DQ41666724-48471B00-D20D-427F-87E2-CFA3907A20C6Q41709332-A3DDC9C0-7630-4FB4-860C-046C7A92C96CQ41721837-B863469F-5EC7-460C-820B-6BC0E2C9783BQ42194740-4D3E3D68-0A63-49E4-94B9-E0A9F2B2853CQ42255811-655DDCA9-B164-4788-A8A9-4BFEA11B0C58
P2860
Natural history of chronic hepatitis B: what exactly has REVEAL revealed?
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Natural history of chronic hepatitis B: what exactly has REVEAL revealed?
@en
type
label
Natural history of chronic hepatitis B: what exactly has REVEAL revealed?
@en
prefLabel
Natural history of chronic hepatitis B: what exactly has REVEAL revealed?
@en
P2093
P2860
P1433
P1476
Natural history of chronic hepatitis B: what exactly has REVEAL revealed?
@en
P2093
Chien-Jen Chen
Hwai-I Yang
Uchenna H Iloeje
P2860
P304
P356
10.1111/J.1478-3231.2012.02805.X
P577
2012-04-17T00:00:00Z